Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 7.5% in June

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 19,600 shares, a drop of 7.5% from the May 31st total of 21,200 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily trading volume, of 10,200 shares, the days-to-cover ratio is presently 1.9 days.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a report on Monday, June 24th. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, May 14th.

Aprea Therapeutics Trading Down 5.7 %

Shares of APRE opened at $3.80 on Wednesday. The business’s fifty day moving average is $4.80 and its 200 day moving average is $5.50. Aprea Therapeutics has a 12-month low of $2.78 and a 12-month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.11. The business had revenue of $0.38 million for the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. On average, equities research analysts expect that Aprea Therapeutics will post -2.57 EPS for the current fiscal year.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.